Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR19024 in advanced solid tumor
NCT05463432Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HR19024 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoint: Maximum Tolerated Dose. Started Aug 2022; status: completed.
02
Drugs
HR19024
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05463432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463432.